Search Results - "TRUCKSIS, Michele"

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis by Henn, Matthew R., O’Brien, Edward J., Diao, Liyang, Feagan, Brian G., Sandborn, William J., Huttenhower, Curtis, Wortman, Jennifer R., McGovern, Barbara H., Wang-Weigand, Sherry, Lichter, David I., Chafee, Meghan, Ford, Christopher B., Bernardo, Patricia, Zhao, Peng, Simmons, Sheri, Tomlinson, Amelia D., Cook, David N., Pomerantz, Roger J., Misra, Bharat K., Auninš, John G., Trucksis, Michele

“…Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of…”
Get full text

Chronic Q Fever in the United States by Karakousis, Petros C, Trucksis, Michele, Dumler, J. Stephen

“…Infections due to Coxiella burnetii, the causative agent of Q fever, are uncommon in the United States. Cases of chronic Q fever are extremely rare and most…”
Get full text

The Vibrio cholerae Genome Contains Two Unique Circular Chromosomes by Trucksis, Michele, Michalski, Jane, Deng, Ying Kang, Kaper, James B.

“…Vibrio cholerae, the etiologic agent of the diarrheal disease cholera, is a Gram-negative bacterium that belongs to the γ subdivision of the family…”
Get full text

Molecular and Physiological Effects of Mycobacterial oxyR Inactivation by PAGAN-RAMOS, Eileen, MASTER, Sharon S, PRITCHETT, Christopher L, REIMSCHUESSEL, Renate, TRUCKSIS, Michele, TIMMINS, Graham S, DERETIC, Vojo

“…Article Usage Stats Services JB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Clonal diversity of Chilean isolates of enterohemorrhagic Escherichia coli from patients with hemolytic-uremic syndrome, asymptomatic subjects, animal reservoirs, and food products by Rios, M, Prado, V, Trucksis, M, Arellano, C, Borie, C, Alexandre, M, Fica, A, Levine, M.M

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection by Feuerstadt, Paul, Louie, Thomas J, Lashner, Bret, Wang, Elaine E.L, Diao, Liyang, Bryant, Jessica A, Sims, Matthew, Kraft, Colleen S, Cohen, Stuart H, Berenson, Charles S, Korman, Louis Y, Ford, Christopher B, Litcofsky, Kevin D, Lombardo, Mary-Jane, Wortman, Jennifer R, Wu, Henry, Auniņš, John G, McChalicher, Christopher W.J, Winkler, Jonathan A, McGovern, Barbara H, Trucksis, Michele, Henn, Matthew R, von Moltke, Lisa

“…A major challenge with the treatment of Clostridioides difficile infection is restoring the antibiotic-associated alterations of bowel flora to a state less…”
Get full text

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial by McGovern, Barbara H, Ford, Christopher B, Henn, Matthew R, Pardi, Darrell S, Khanna, Sahil, Hohmann, Elizabeth L, O’Brien, Edward J, Desjardins, Christopher A, Bernardo, Patricia, Wortman, Jennifer R, Lombardo, Mary-Jane, Litcofsky, Kevin D, Winkler, Jonathan A, McChalicher, Christopher W J, Li, Sunny S, Tomlinson, Amelia D, Nandakumar, Madhumitha, Cook, David N, Pomerantz, Roger J, Auninš, John G, Trucksis, Michele

“…Abstract Background Recurrent Clostridioides difficile infection (rCDI) is associated with loss of microbial diversity and microbe-derived secondary bile…”
Get full text

Tu2019 - Engraftment of Ser-287, an Investigational Microbiome Therapeutic, is Related to Clinical Remission in a Placebo-Controlled, Double-Blind Randomized Trial (Seres-101) in Patients with Active Mild to Moderate Ulcerative Colitis (UC) by Simmons, Sheri, Diao, Liyang, O'Brien, Edward, Chafee, Meghan, Zhao, Jeff, Bernardo, Patricia, Cook, David, Trucksis, Michele, Henn, Matthew R.

Get full text

Fr572 24-WEEK EFFICACY AND SAFETY DATA FROM ECOSPOR-III, A PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR TREATMENT OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION by Korman, Louis, Lashner, Bret, Kraft, Colleen, Sims, Matthew, Wang, Elaine E., Brady, Kelly, Ford, Christopher B., Lombardo, Mary-Jane, Litcofsky, Kevin D., Mahoney, Jennifer C., McChalicher, Christopher W., Winkler, Jonathan, Garant, Sarah, Mcgovern, Babara, McMullen, Erin, Henn, Matthew R., Trucksis, Michele, von Moltke, Lisa

Get full text

85 - SER-287, an Investigational Microbiome Therapeutic, Induces Remission and Endoscopic Improvement in a Placebo-Controlled, Double-Blind Randomized Trial in Patients with Active Mild-to-Moderate Ulcerative Colitis by Bharat, Misra, Curran, John, Herfarth, Hans H., Jagarlamudi, Kiran, Oneto, Caterina, Bhandari, Bal R., Wiener, Gregory, Kerman, David H., Moss, Alan C., Pomerantz, Roger, Zhao, Jeff, Bernardo, Patricia, Simmons, Sheri, Diao, Liyang, O'Brien, Edward, Henn, Matthew R., Trucksis, Michele

Get full text

1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes by Ford, Christopher, Henn, Matthew, Bryant, Jessica, Diao, Liyang, Wortman, Jennifer, Tomlinson, Amelia, Litcofsky, Kevin, Bernardo, Patricia, McGovern, Barbara, Aunins, John G, Cook, David N, Trucksis, Michele

Get full text

Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation by Stroh, Mark, Talaty, Jennifer, Sandhu, Punam, McCrea, Jacqueline, Patnaik, Amita, Tolcher, Anthony, Palcza, John, Orford, Keith, Breidinger, Sheila, Narasimhan, Narayana, Panebianco, Deborah, Lush, Richard, Papadopoulos, Kyriakos P., Wagner, John A., Trucksis, Michele, Agrawal, Nancy

“…Ridaforolimus, a unique non‐prodrug analog of rapamycin, is a potent inhibitor of mTOR under development for cancer treatment. In vitro data suggest…”
Get full text

621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner by Henn, Matthew, Ford, Christopher, O’Brien, Edward, Wortman, Jennifer, Diao, Liyang, Desjardins, Christopher, Tomlinson, Amelia, Litcofsky, Kevin, Wilcox, Mark, Buckley, Anthony, Bernardo, Patricia, McGovern, Barbara, Aunins, John G, Cook, David N, Trucksis, Michele

Get full text

Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI) by Henn, Matthew, Ford, Christopher, O’Brien, Edward, Wortman, Jennifer, Simmons, Sheri, Diao, Liyang, Litcofsky, Kevin, Bernardo, Patricia, Aunins, John, Cook, David, Trucksis, Michele

“…Abstract Background Recurrence of CDI occurs within a few weeks after treatment due to antibiotic-induced dysbiosis. SER-109, an investigational,…”
Get full text

The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus by Stroh, Mark, Palcza, John, McCrea, Jacqueline, Marsilio, Sabrina, Breidinger, Sheila, Panebianco, Deborah, Johnson-Levonas, Amy, Kraft, Walter K., Orford, Keith, Murphy, Gail, Agrawal, Nancy, Trucksis, Michele, Wagner, John A., Iwamoto, Marian

“…Purpose Ridaforolimus is an inhibitor of the mammalian target of rapamycin protein, with potent activity in vitro and in vivo. Ridaforolimus is primarily…”
Get full text

The minimal impact of food on the pharmacokinetics of ridaforolimus by Stroh, Mark, Li, Xiaodong, Marsilio, Sabrina, Panebianco, Deborah, Johnson-Levonas, Amy, Juan, Axel, Orford, Keith, Agrawal, Nancy, Trucksis, Michele, Wagner, John A., Murphy, Gail, Iwamoto, Marian

“…Purpose Ridaforolimus, a potent inhibitor of the mammalian target of rapamycin (mTOR), is under development for the treatment for solid tumors. This…”
Get full text

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer by Lush, Richard M., Patnaik, Amita, Sullivan, Daniel, Papadopoulos, Kyriakos P., Trucksis, Michele, McCrea, Jacqueline, Cerchio, Kristine, Li, Xiaodong, Stroh, Mark, Selverian, Diana, Orford, Keith, Ebbinghaus, Scot, Agrawal, Nancy, Iwamoto, Marian, Wagner, John A., Tolcher, Anthony

“…Purpose This dedicated QTc study was designed to evaluate the effect of the mammalian target of rapamycin inhibitor, ridaforolimus, on the QTc interval in…”
Get full text

Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus by Ng, E Y, Trucksis, M, Hooper, D C

“…Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon…”
Get full text

Goldfish, Carassius auratus, a novel animal model for the study of Mycobacterium marinum pathogenesis by TALAAT, A. M, REIMSCHUESSEL, R, WASSERMAN, S. S, TRUCKSIS, M

“…We have developed an animal model for studying mycobacterial pathogenesis using Mycobacterium marinum and the goldfish, Carassius auratus. Goldfish are…”
Get full text

The American cotton rat: A novel model for pulmonary tuberculosis by Elwood, Robert L, Wilson, Samuel, Blanco, Jorge C.G, Yim, Kevin, Pletneva, Luba, Nikonenko, Boris, Samala, Rowena, Joshi, Swati, Hemming, Val G, Trucksis, Michele

“…Summary Several animal models are used to study Mycobacterium tuberculosis (MTB) infections, but none is a fully ideal model of human disease. The American…”
Get full text